Creative Bio-Peptides, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
2
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jun 10, 2027The maintenance fee for Uses of peptides to treat brain injury and disease (US 10,501,494) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Oct 21, 2027The maintenance fee for Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH) (US 10,624,944) comes due Oct 21, 2027. Unpaid by Apr 21, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,973,906 | Therapeutic peptides and vaccines In force · USPTO record | In force | USPTO record | |
| US 10,071,153 | Therapeutic peptides and vaccines In force · USPTO record | In force | USPTO record | |
| US 10,130,674 | Modified peptide that reduces pain in peripheral neuropathy In force · USPTO record | In force | USPTO record | |
| US 10,501,494 | Uses of peptides to treat brain injury and disease In force · USPTO record | In force | USPTO record | |
| US 10,624,944 | Anti-inflammatory peptides for treating non-alcoholic steatohepatitis (NASH) In force · USPTO record | In force | USPTO record | |
| US RE50,563 | Use of an all-D-pentapeptide chemokine antagonist to reduce opioid dose in a person with pain In force · USPTO record | In force | USPTO record | |
| US RE50,630 | Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with Pain In force · Low confidence | In force | Low confidence | |
| US 11,510,961 | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof In force · USPTO record | In force | USPTO record | |
| US 12,257,283 | Methods and compositions for use of a chemokine receptor antagonist peptide to treat addiction, substance abuse disorders or symptoms thereof In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 9: 1 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 4 no status recorded
Showing 1 to 7 of 7, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/053,588 | Feb 14, 2025 | No status recorded | |
| 18/512,201 | Oral Peptide Antagonists of Multiple Chemokine Receptors for Reversing Loss of Synapses and Dendritic Spines | Nov 17, 2023 | Pending |
| 18/560,768 | Compositions and Methods for Treating Persistent Postsurgical Pain | Jun 9, 2022 | Pending |
| 18/559,874 | Compositions and Methods for Treating Neuropathy | May 20, 2022 | Pending |
| 17/170,790 | Feb 8, 2021 | No status recorded | |
| 16/038,144 | Jul 17, 2018 | No status recorded | |
| 15/989,823 | May 25, 2018 | No status recorded |